PD1/NFAT-Luc/Jurkat
CBP74018
| I. Background | |
| 腫瘤細胞可以借助免疫檢查點受體逃避機體免疫系統(tǒng)的識別和殺傷，因此阻斷免疫檢 查點受體可能是一種廣泛有效的腫瘤免疫治療方法。目前，抗 PD-1/PD-L1 抗體雖然比較 成熟，與抗 CTLA4 抗體類似，但由于存在耐藥性，患者的總體有效率較低，因此尋找新 的腫瘤免疫治療靶點迫在眉睫。 Programmed Cell Death Protein 1 (PD-1)，一種在激活的 T 細胞上表達的受體，與其配 體 PD-L1 和 PD-L2 結(jié)合，負向調(diào)節(jié)免疫反應。 PD-1 配體存在于大多數(shù)癌癥中，PD-1:PD- L1/2 相互作用會抑制 T 細胞活性，并使癌細胞逃避免疫監(jiān)視。 PD1/PDL1 信號轉(zhuǎn)導通路是 腫瘤免疫抑制的重要組成部分，可以抑制 T 淋巴細胞的興奮，增強腫瘤細胞的免疫耐受， 從而實現(xiàn)腫瘤免疫逃逸。PD1 與 PDL1 結(jié)合可以減弱 T 細胞介導的免疫監(jiān)視，導致免疫反 應缺失，甚至導致 T 細胞凋亡。PD1/PDL1 抑制劑可解除抗腫瘤 T 細胞的免疫抑制，從而 導致 T 細胞增殖并滲透到腫瘤微環(huán)境中并誘導抗腫瘤反應。PD-1:PD-L1/2 通路還參與調(diào)節(jié) 自身免疫反應，使這些蛋白質(zhì)成為多種癌癥以及多發(fā)性硬化癥、關節(jié)炎、狼瘡和 I 型糖尿 病的有希望的治療靶點。酪氨酸磷酸酶 SHP2 是 T 細胞功能的關鍵調(diào)節(jié)因子，它介導 TCR 下游的激活信號以及 PD-1 下游的抑制信號。 |
|
| II. Description | |
PD1 NFAT-Luc Jurkat 報告基因藥靶模型很好的模擬了體內(nèi) PD1&PDL1/PDL2 的信號轉(zhuǎn) 導過程，原理見下圖所示。  Figure 1. PD1 NFAT-Luc Jurkat 細胞模型原理圖 |
|
| III. Introduction | |
| Host Cell: | Jurkat |
| Expressed gene: | PD1、NFAT-Luciferase |
| Stability: | 32 passages (in-house test, that not means the cell line will be instable beyond the passages we tested.) |
| Synonym(s): | Programmed cell death 1, PDCD1, PD-1, PD1, SLEB2, CD279, HPD-L, PD1/NFAT, PD-1 NFAT, PD-1/NFAT |
| Freeze Medium: | 90% FBS+10% DMSO |
| Culture Medium: | RPMI-1640+10%FBS+800μg/ml hygromycin+1μg/ml puromycin |
| Mycoplasma Testing: | Negative |
| Storage: | Liquid nitrogen |
| Application(s): | Functional(Report Gene) Assay |
| IV. Description of Host Cell Line | |
| Organism: | Homo sapiens, human |
| Tissue: | Peripheral blood |
| Disease: | Acute T cell leukemia |
| Morphology: | Lymphoblast |
| Growth Properties: | Suspension |
| Ⅴ. Representative Data | |
|
|
|
|
Figure 2. Recombinant PD1/NFAT-Luc/Jurkat stably expressing PD1. |
|
|
Figure 3. Detect Luciferase assay by Ultra Luciferase Detection Kit CBPH0001（we strongly suggest to purchase from Cobioer).Dose response of Anti-PD-1 Neutralizing Antibody in PD1 NFAT-Luc Jurkat(C16) with PDL1 TCR Activator CHO (C5).Dose response of Anti-PD-L1(CD274) Neutralizing Antibody in PD1 NFAT-Luc Jurkat(C16) with PDL1 TCR Activator CHO (C5). |
|
|
|
|
|
Figure 4. Detect Luciferase assay by Ultra Luciferase Detection Kit CBPH0001（we strongly suggest to purchase from Cobioer). Dose response of Anti-PD1 Neutralizing Antibody in PD1 NFAT-Luc Jurkat(C16) with PDL2 TCR Activator CHO(C1). |
|
|
Figure 5. Detect Luciferase assay by Ultra Luciferase Detection Kit CBPH0001（we strongly suggest to purchase from Cobioer). Dose Response of PD1 Agonist Antibody in PD1 NFAT-Luc Jurkat（C16)）With FCγR aAPC Cell(C1). |
|
